CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Ranked in the list of Forbes on the “Best Enterprises Under a Billion”
2022-07-08

Ranked in the list of Forbes on the “Best Enterprises Under a Billion”

Awarded the “Best Listed Company” by Ta Kung Pao

Awarded the “Best Listed Company” by Ta Kung Pao

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”

Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China

Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China

Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号